{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:29:51Z","timestamp":1792801791553,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier","isbn-type":[{"value":"9780443432361","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.acr.2026.01.017","type":"book-chapter","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:17:09Z","timestamp":1777288629000},"page":"1-22","source":"Crossref","is-referenced-by-count":1,"title":["Oncolytic viruses in cutaneous oncology: Mechanisms, clinical applications, and future directions"],"prefix":"10.1016","author":[{"given":"Goranit","family":"Sakunchotpanit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir K.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhi","family":"Kanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Z.","family":"Rohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod E.","family":"Nambudiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/bs.acr.2026.01.017_bib0001","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020028454","article-title":"Malignant melanoma: Skin cancer-diagnosis, prevention, and treatment","volume":"30","author":"Ahmed","year":"2020","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"5","key":"10.1016\/bs.acr.2026.01.017_bib0002","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.ymthe.2025.03.035","article-title":"Oncolytic viruses as cancer therapeutics: From mechanistic insights to clinical translation","volume":"33","author":"Alwithenani","year":"2025","journal-title":"Mol Ther"},{"issue":"25","key":"10.1016\/bs.acr.2026.01.017_bib0003","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/bs.acr.2026.01.017_bib0004","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: A randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/bs.acr.2026.01.017_bib0005","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.ymthe.2024.12.054","article-title":"Understanding the interplay between oHSV and the host immune system: Implications for therapeutic oncolytic virus development","volume":"33","author":"Ayele","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/bs.acr.2026.01.017_bib0006","doi-asserted-by":"crossref","first-page":"110478","DOI":"10.1016\/j.radonc.2024.110478","article-title":"A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors","volume":"200","author":"Barker","year":"2024","journal-title":"Radiother Oncol"},{"issue":"10","key":"10.1016\/bs.acr.2026.01.017_bib0007","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11912-018-0729-3","article-title":"The role of oncolytic viruses in the treatment of melanoma","volume":"20","author":"Bayan","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/bs.acr.2026.01.017_bib0008","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/bs.mie.2019.08.011","article-title":"Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR\/Cas9 genetic disruption","volume":"635","author":"Bommareddy","year":"2020","journal-title":"Methods Enzymol"},{"issue":"8","key":"10.1016\/bs.acr.2026.01.017_bib0009","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/bs.acr.2026.01.017_bib0010","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1080\/21645515.2015.1037058","article-title":"Oncolytic viruses: From bench to bedside with a focus on safety","volume":"11","author":"Buijs","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/bs.acr.2026.01.017_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189110","article-title":"A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment","volume":"1879","author":"Chattopadhyay","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6","key":"10.1016\/bs.acr.2026.01.017_bib0012","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3390\/cancers12061699","article-title":"Optimizing Oncolytic viral design to enhance antitumor efficacy: Progress and challenges","volume":"12","author":"Chaurasiya","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/bs.acr.2026.01.017_bib0013","first-page":"830","article-title":"Progress in oncolytic viruses modified with nanomaterials for intravenous application","volume":"20","author":"Chen","year":"2023","journal-title":"Cancer Biol Med"},{"key":"10.1016\/bs.acr.2026.01.017_bib0014","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.canlet.2021.09.040","article-title":"Stereotactic body radiation combined with oncolytic vaccinia virus induces potent anti-tumor effect by triggering tumor cell necroptosis and DAMPs","volume":"523","author":"Chen","year":"2021","journal-title":"Cancer Lett"},{"issue":"17","key":"10.1016\/bs.acr.2026.01.017_bib0015","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/bs.acr.2026.01.017_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006270","article-title":"Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial","volume":"11","author":"Chesney","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/bs.acr.2026.01.017_bib0017","doi-asserted-by":"crossref","unstructured":"Chesney, J. A., Ribas, A., Long, G. V., Kirkwood, J. M., Dummer, R., Puzanov, I., Hoeller, C., Gajewski, T. F., Gutzmer, R., Rutkowski, P., Demidov, L., Arenberger, P., Shin, S. J., Ferrucci, P. F., Haydon, A., Hyngstrom, J., van Thienen, J. V., Haferkamp, S., Malvehy Guilera, J., \u2026 Gogas, H. (2023). Randomized, double\u2010blind, placebo\u2010controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol, 41(3), 528\u2010540. https:\/\/doi.org\/10.1200\/JCO.22.00343.","DOI":"10.1200\/JCO.22.00343"},{"issue":"9","key":"10.1016\/bs.acr.2026.01.017_bib0018","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-17-0439","article-title":"Merkel cell carcinoma in the age of immunotherapy: Facts and hopes","volume":"24","author":"Colunga","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/bs.acr.2026.01.017_bib0019","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/21645515.2017.1412896","article-title":"Talimogene laherparepvec: First in class oncolytic virotherapy","volume":"14","author":"Conry","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"23","key":"10.1016\/bs.acr.2026.01.017_bib0020","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMra2034861","article-title":"Recent advances in the treatment of melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.acr.2026.01.017_bib0021","article-title":"Advances in preclinical and clinical studies of oncolytic virus combination therapy","volume":"15","author":"Du","year":"2025","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/bs.acr.2026.01.017_bib0022","article-title":"Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors","volume":"7","author":"Feola","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.acr.2026.01.017_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108103","article-title":"Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment","volume":"236","author":"Feola","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/bs.acr.2026.01.017_bib0024","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/cancers13061383","article-title":"Talimogene laherparepvec (T-VEC): An intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.acr.2026.01.017_bib0025","doi-asserted-by":"crossref","first-page":"1656984","DOI":"10.3389\/fmicb.2025.1656984","article-title":"TG6002 oncolytic vaccinia virus and chemotherapy synergy: A promising strategy for pancreatic ductal adenocarcinoma","volume":"16","author":"Foloppe","year":"2025","journal-title":"Front Microbiol"},{"issue":"10","key":"10.1016\/bs.acr.2026.01.017_bib0026","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci"},{"issue":"24","key":"10.1016\/bs.acr.2026.01.017_bib0027","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1002\/1873-3468.13691","article-title":"State-of-the-art human adenovirus vectorology for therapeutic approaches","volume":"593","author":"Gao","year":"2019","journal-title":"FEBS Lett"},{"issue":"10","key":"10.1016\/bs.acr.2026.01.017_bib0028","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s10529-021-03173-3","article-title":"The application of oncolytic viruses in cancer therapy","volume":"43","author":"Gao","year":"2021","journal-title":"Biotechnol Lett"},{"issue":"10","key":"10.1016\/bs.acr.2026.01.017_bib0029","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1634\/theoncologist.2018-0718","article-title":"Recent therapeutic advances and change in treatment paradigm of patients with Merkel cell carcinoma","volume":"24","author":"Garcia-Carbonero","year":"2019","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/bs.acr.2026.01.017_bib0030","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1089\/hum.2017.139","article-title":"Capsid engineering of adenovirus vectors: Overcoming early vector-host interactions for therapy","volume":"28","author":"Hagedorn","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"17\u201318","key":"10.1016\/bs.acr.2026.01.017_bib0031","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1089\/hum.2023.122","article-title":"Personalizing oncolytic virotherapy","volume":"34","author":"Hamdan","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"9","key":"10.1016\/bs.acr.2026.01.017_bib0032","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/bs.acr.2026.01.017_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003836","article-title":"From scourge to cure: Tumour-selective viral pathogenesis as a new strategy against cancer","volume":"10","author":"Ilkow","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/bs.acr.2026.01.017_bib0034","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.omto.2021.12.016","article-title":"Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade","volume":"24","author":"Inoue","year":"2022","journal-title":"Mol Ther Oncol"},{"issue":"11","key":"10.1016\/bs.acr.2026.01.017_bib0035","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/bs.acr.2026.01.017_bib0036","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.3390\/pharmaceutics14091811","article-title":"Strategies for advanced oncolytic virotherapy: Current technology innovations and clinical approaches","volume":"14","author":"Ji","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/bs.acr.2026.01.017_bib0037","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jconrel.2021.02.018","article-title":"Overcoming the barriers to optimization of adenovirus delivery using biomaterials: Current status and future perspective","volume":"332","author":"Kasala","year":"2021","journal-title":"J Control Release"},{"issue":"9","key":"10.1016\/bs.acr.2026.01.017_bib0038","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/bs.acr.2026.01.017_bib0039","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular pathways: Mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/bs.acr.2026.01.017_bib0040","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3390\/ijms22052417","article-title":"Capsid and genome modification strategies to reduce the immunogenicity of adenoviral vectors","volume":"22","author":"Kreppel","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"24","key":"10.1016\/bs.acr.2026.01.017_bib0041","doi-asserted-by":"crossref","first-page":"19976","DOI":"10.18632\/oncotarget.5116","article-title":"Going viral: A review of replication-selective oncolytic adenoviruses","volume":"6","author":"Larson","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/bs.acr.2026.01.017_bib0042","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: A review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/bs.acr.2026.01.017_bib0043","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/cancers12061416","article-title":"Efficacy and safety of oncolytic viruses in randomized controlled trials: A systematic review and meta-analysis","volume":"12","author":"Li","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/bs.acr.2026.01.017_bib0044","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: Basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"10400","key":"10.1016\/bs.acr.2026.01.017_bib0045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","article-title":"Cutaneous melanoma","volume":"402","author":"Long","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/bs.acr.2026.01.017_bib0046","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/bs.acr.2026.01.017_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113986","article-title":"Virotherapy: From single agents to combinatorial treatments","volume":"177","author":"Malfitano","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/bs.acr.2026.01.017_bib0048","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic viral therapy and the immune system: A double-edged sword against cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/bs.acr.2026.01.017_bib0049","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2174\/138920112800958931","article-title":"The molecular basis of herpesviruses as oncolytic agents","volume":"13","author":"Menotti","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/bs.acr.2026.01.017_bib0050","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fonc.2017.00114","article-title":"Current immunotherapeutic strategies to enhance oncolytic virotherapy","volume":"7","author":"Meyers","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/bs.acr.2026.01.017_bib0051","doi-asserted-by":"crossref","unstructured":"Mirbahari, S. N., Da Silva, M., Mu\u00f1oz Z\u00fa\u00f1iga, A. I., Kooshki Zamani, N., St\u2010Laurent, G., Totonchi, M., & Azad, T. (2024). Recent progress in combination therapy of oncolytic vaccinia virus. Front Immun, 15, 1272351. https:\/\/doi.org\/10.3389\/fimmu.2024.1272351.","DOI":"10.3389\/fimmu.2024.1272351"},{"issue":"7","key":"10.1016\/bs.acr.2026.01.017_bib0052","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/ph17070916","article-title":"Where are we now with oncolytic viruses in melanoma and nonmelanoma skin malignancies?","volume":"17","author":"Nassief","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"20","key":"10.1016\/bs.acr.2026.01.017_bib0053","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.3390\/ijms21207743","article-title":"Combination immunotherapy using oncolytic virus for the treatment of advanced solid tumors","volume":"21","author":"Oh","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/bs.acr.2026.01.017_bib0054","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jdin.2024.11.010","article-title":"Oncolytic viral therapy for nonmelanoma skin cancer and cutaneous lymphoma \u2013 a systematic review","volume":"20","author":"Ong","year":"2025","journal-title":"JAAD Int"},{"issue":"9","key":"10.1016\/bs.acr.2026.01.017_bib0055","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3390\/vaccines11091448","article-title":"Oncolytic viruses: An inventory of shedding data from clinical trials and elements for the environmental risk assessment","volume":"11","author":"Onnockx","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"13","key":"10.1016\/bs.acr.2026.01.017_bib0056","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1158\/1078-0432.CCR-15-2709","article-title":"Talimogene laherparepvec for the treatment of advanced melanoma","volume":"22","author":"Ott","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/bs.acr.2026.01.017_bib0057","article-title":"Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy","volume":"13","author":"Palanivelu","year":"2022","journal-title":"Front Immunol"},{"issue":"559","key":"10.1016\/bs.acr.2026.01.017_bib0058","doi-asserted-by":"crossref","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/bs.acr.2026.01.017_bib0059","doi-asserted-by":"crossref","first-page":"9051","DOI":"10.3390\/ijms22169051","article-title":"Immunomodulatory arming factors-the current paradigm for oncolytic vectors relies on immune stimulating molecules","volume":"22","author":"Peters","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/bs.acr.2026.01.017_bib0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s43018-024-00879-x","article-title":"Efficacy and tolerability of neoadjuvant therapy with talimogene laherparepvec in cutaneous basal cell carcinoma: A phase II trial (NeoBCC trial)","volume":"6","author":"Ressler","year":"2025","journal-title":"Nat Cancer"},{"issue":"5","key":"10.1016\/bs.acr.2026.01.017_bib0061","doi-asserted-by":"crossref","first-page":"151","DOI":"10.31083\/j.fbl2705151","article-title":"Oncolytic viruses as an adjunct to immune checkpoint inhibition","volume":"27","author":"Ripp","year":"2022","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/bs.acr.2026.01.017_bib0062","doi-asserted-by":"crossref","first-page":"114120","DOI":"10.1016\/j.ejca.2024.114120","article-title":"Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115","volume":"207","author":"Robert","year":"2024","journal-title":"Europ J Cancer"},{"issue":"9","key":"10.1016\/bs.acr.2026.01.017_bib0063","doi-asserted-by":"crossref","DOI":"10.1111\/exd.15169","article-title":"Treatment of malignant melanoma with coxsackievirus A21 (V937): An emerging oncolytic virotherapy","volume":"33","author":"Sakunchotpanit","year":"2024","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1016\/bs.acr.2026.01.017_bib0064","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/v15010204","article-title":"The adenovirus vector platform: Novel insights into rational vector design and lessons learned from the COVID-19 vaccine","volume":"15","author":"Sallard","year":"2023","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/bs.acr.2026.01.017_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188880","article-title":"An update on Merkel cell carcinoma","volume":"1878","author":"Sergi","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"10.1016\/bs.acr.2026.01.017_bib0066","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: Progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/bs.acr.2026.01.017_bib0067","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.3390\/ijms22126305","article-title":"Merkel cell carcinoma from molecular pathology to novel therapies","volume":"22","author":"Stachyra","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/bs.acr.2026.01.017_bib0068","doi-asserted-by":"crossref","unstructured":"Stahlie, E. H. A., Mulder, E. E. A. P., Reijers, S., Balduzzi, S., Zuur, C. L., Klop, W. M. C., van der Hiel, B., Van de Wiel, B. A., Wouters, M. W. J. M., Schrage, Y. M., van Houdt, W. J., Grunhagen, D. J., & van Akkooi, A. C. J. (2022). Single agent talimogene laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta\u2010analysis. Crit Rev Onco\/Hematol, 175, 103705. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103705.","DOI":"10.1016\/j.critrevonc.2022.103705"},{"key":"10.1016\/bs.acr.2026.01.017_bib0069","doi-asserted-by":"crossref","first-page":"216169","DOI":"10.1016\/j.canlet.2023.216169","article-title":"Radiation combined with oncolytic vaccinia virus provides pronounced antitumor efficacy and induces immune protection in an aggressive glioblastoma model","volume":"562","author":"Storozynsky","year":"2023","journal-title":"Cancer Lett"},{"issue":"5","key":"10.1016\/bs.acr.2026.01.017_bib0070","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jaad.2024.05.095","article-title":"Current and emerging intralesional immunotherapies in cutaneous oncology","volume":"91","author":"Stull","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/bs.acr.2026.01.017_bib0071","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1158\/0008-5472.CAN-19-2062","article-title":"Exploiting preexisting immunity to enhance oncolytic cancer immunotherapy","volume":"80","author":"T\u00e4htinen","year":"2020","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/bs.acr.2026.01.017_bib0072","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3390\/cancers16111951","article-title":"Combined regional approach of talimogene laherparepvec and radiotherapy in the treatment of advanced melanoma","volume":"16","author":"Tam","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/bs.acr.2026.01.017_bib0073","article-title":"Talimogene laherparepvec (T-VEC): Expanding horizons in oncolytic viral therapy across multiple cancer types","author":"Tan","year":"2025","journal-title":"Anticancer Agents Med Chem"},{"issue":"1","key":"10.1016\/bs.acr.2026.01.017_bib0074","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/bs.acr.2026.01.017_bib0075","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4049\/jimmunol.1701021","article-title":"Critical interactions between immunogenic cancer cell death, oncolytic viruses, and the immune system define the rational design of combination immunotherapies","volume":"200","author":"van Vloten","year":"2018","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/bs.acr.2026.01.017_bib0076","first-page":"325","article-title":"Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas","volume":"20","author":"Wang","year":"2023","journal-title":"Cancer Biol Med"},{"issue":"49","key":"10.1016\/bs.acr.2026.01.017_bib0077","doi-asserted-by":"crossref","first-page":"81208","DOI":"10.18632\/oncotarget.12820","article-title":"Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis","volume":"7","author":"Wilkinson","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/bs.acr.2026.01.017_bib0078","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints\u2014PD-1, PD-L1, CTLA-4\u2014new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metast Rev"},{"issue":"24","key":"10.1016\/bs.acr.2026.01.017_bib0079","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1056\/NEJMra2206348","article-title":"Squamous-cell carcinoma of the skin","volume":"388","author":"Wysong","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/bs.acr.2026.01.017_bib0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.copbio.2019.11.016","article-title":"Design and application of oncolytic viruses for cancer immunotherapy","volume":"65","author":"Yl\u00f6sm\u00e4ki","year":"2020","journal-title":"Curr Opin Biotechnol"},{"issue":"1","key":"10.1016\/bs.acr.2026.01.017_bib0081","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12943-020-01275-6","article-title":"Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol Cancer"},{"issue":"3","key":"10.1016\/bs.acr.2026.01.017_bib0082","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3390\/jcm12031098","article-title":"Talimogene laherparepvec (T-VEC): A review of the recent advances in cancer therapy","volume":"12","author":"Zhang","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/bs.acr.2026.01.017_bib0083","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic viruses for cancer therapy: Barriers and recent advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol Ther Oncolytics"},{"issue":"12","key":"10.1016\/bs.acr.2026.01.017_bib0084","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.3390\/cancers14122873","article-title":"Beyond immunotherapy: Seizing the momentum of oncolytic viruses in the ideal platform of skin cancers","volume":"14","author":"Ziogas","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Advances in Cancer Research","Viruses as Therapeutic Agents for Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X26000187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X26000187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:58:09Z","timestamp":1780592289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X26000187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443432361"],"references-count":84,"URL":"https:\/\/doi.org\/10.1016\/bs.acr.2026.01.017","relation":{},"ISSN":["0065-230X"],"issn-type":[{"value":"0065-230X","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}